Oral intake of new probiotic formulations may improve the course of atopic dermatitis (AD) in a young population.
A topic dermatitis (AD) is a chronic recurrent inflammatory skin disease characterized by intense pruritus, inflammation, and skin barrier disruption. The prevalence of AD is approximately 3% to 10% in adults and up to 20% in children worldwide. 1, 2 The first symptoms usually develop during childhood, and approximately 50% of cases are diagnosed in the first year of life. Atopic dermatitis significantly reduces the quality of life of patients and their families. Moreover, patients with AD have an increased risk of other atopic disorders, including asthma, allergic rhinitis, and chronic sinusitis. 3, 4 As occurs in other atopic disorders, a predominance of T helper 2 cells rather than T helper 1 causes an imbalance that might also aggravate the pathogenesis of AD, increasing IgE and activating interleukins. 5, 6 Another point to consider is skin barrier integrity. Filaggrin interacts with intermediate filaments, particularly keratins, causing their aggregation into macrofibrils. Defects in filaggrin cause dysfunctions in the skin barrier, resulting in decreased protection from microbes and allergens. 7 Clinically, cutaneous manifestations related to AD include erythema, edema and/or papules, exudate, excoriation, and lichenification, as well as the resulting symptoms (pruritus and loss of sleep). 3, 8 Topical corticosteroids have been the keystone of pharmacological treatments for mild to moderate AD. Alternatively, cases of moderate-to-severe AD are treated with long-term applications of topical corticosteroids, 9 with topical calcineurin inhibitors providing second-line effective agents. However, long-term data for these medications are lacking for pediatric patients. 10 In cases of severe refractory disease, patients might benefit from a short course of systemic therapy with immunosuppressants such as corticosteroids, cyclosporine, and azathioprine, but these drugs have a potentially more severe adverse effect profile and risks of rebound after treatment discontinuation. 11, 12 During recent years, many authors have suggested an association between a disruption in intestinal barrier function and the origin of AD, mediated by immunological activation leading to a type 2 dominant inflammation. 13 In this respect, gut microbiota may play an important immunomodulatory role in the development of normal immune tolerance. 14, 15 Recently an analysis of the gut microbiota of patients with AD has shown an intraspecies compositional change in Faecalibacterium prausnitzii that reduces the number of high butyrate and propionate producers. 16 Butyrate and propionate are microbial-produced short-chain fatty acids with an anti-inflammatory role. 17 Moreover, butyrate has been shown to be a key player in maintaining gut barrier integrity. 18 Therefore, reduced levels in the microbiota of both butyrate and propionate producers may result in a pro-inflammatory state in the gut and a loss of barrier integrity. All these data indicate the potential role of probiotics as microbiota recovery players, and consequently as potential nutritional supplements in AD treatment. [19] [20] [21] The primary goal of the present study was to determine the efficacy of a mixture of probiotics in improving the SCORAD (Scoring Atopic Dermatitis) index 22 and in reducing the percentage of days with topical steroid treatment during flares in patients with moderate AD.
Methods

Study Design
The study design was a double-blind, 2-arm placebo-controlled trial with stratified randomization by baseline variables (ratio, 1:1). The study received approval from the Ethics Committee for Clinical Research of the Hospital General Universitario de Alicante, and the Spanish Medicines Agency. There was no change to the trial protocol (Supplement 1) after it commenced.
Study Population
Inclusion criteria of the protocol were as follows: children between 4 and 17 years old, with a diagnosis of AD that meets the Hanifin and Rajka criteria (eTable 1 in Supplement 2) and moderate SCORAD index (from 20 to 40) 22 who had been prescribed topical steroids for the treatment of AD. Participants were also required to be currently consuming a high-quality Mediterranean diet with a Mediterranean Diet Quality Index (KIDMED) 23 score more than 7. Written informed consent was obtained from parents or a legal representative (and the child if >12 years). Among the exclusion criteria, patients were ineligible for the study if they had used systemic corticosteroids, methotrexate, cyclosporine, or anti-tumor necrosis factor drugs in the previous 3 months, antibiotics in the previous 2 weeks, or had a concomitant diagnosis of intolerance to gluten and/or lactose or signs of bacterial infection (the Trial Protocol in Supplement 1 provides a complete list of exclusion criteria). erized randomization list that been previously prepared for each stratum by the principal investigator of the study (V.N.-L.).
Interventions
All patients received treatment during the 12-week study period with topical methylprednisolone aceponate, moisturizer, and 1 oral antihistamine, according to the guidelines for the management of AD. 9 Participants in the probiotic group received daily a pill containing 10 9 colony-forming units (CFUs) of a mixture of the 3 probiotic strains in a 1:1:1 ratio, freeze-dried powder with maltodextrin as a carrier, and participants in the placebo group received a pill containing only maltodextrin. The probiotic and placebo pills were matched for size, shape, and volume of contents (gelatin capsules of 9.85 × 16.4 mm) and were dispensed by the pharmacy department staff.
The product was designed not as a single strain but as a bacteria mixture with lactobacilli and bifidobacteria because previous AD clinical trials with probiotics have obtained better results with mixed products. 24 The mixture was composed of Bifidobacterium lactis CECT 8145, B longum CECT 7347, and Lactobacillus casei CECT 9104. The blend was selected on the basis of previous data: oxidative stress has been associated with AD, 25 and strain B lactis CECT 8145 has previously shown antioxidant properties in the Caenorhabditis elegans model. 26 Strain B longum CECT 7347 has an anti-inflammatory profile, previously demonstrated in both preclinical and clinical studies, 27, 28 and it modulates the gut microbiota. 
Outcome Measurements
Two primary outcomes were compared between the trial arms to assess the treatment effect: (1) change in SCORAD index between baseline and 12 weeks of follow-up and (2) the proportion of days of topical steroid use during flares within the 12 weeks of follow-up. The SCORAD index was measured at the time of inclusion and every 4 weeks until the end of the 12-week follow-up period. The number of days of topical steroid use during flares was recorded biweekly until week 12. A flare was defined as a worsening of the disease leading to use of topical corticosteroids for at least 3 consecutive days (so steroid use on only 1 or 2 isolated days was not considered a flare). Secondary outcomes were laboratory values. Peripheral blood samples were collected at baseline and after 12 weeks of treatment and analyzed for routine biochemical laboratory values and for interleukin 4 (IL-4), IL-5, IL-10, and IL-13 levels.
Sample Size
According to the trial protocol, 25 patients per group would be needed to detect a difference of clinical improvement as evaluated by the SCORAD index, assuming 5% loss to follow-up, type I error of .05, and 80% power to detect a difference of 4.13 units on the SCORAD index with a standard deviation of 5 units between the 2 groups on a 2-sided t test.
Statistical Analysis
Data were analyzed as intention to treat, and the last available value was not carried forward for missing observations. Quantitative variables were summarized as means and standard deviations or median and interquartile range, and categorical variables were summarized with proportions.
We used linear mixed-effects models with a group-byweek interaction term to compare the mean SCORAD score between groups at weeks 4, 8, and 12. Participant-level random intercepts accounted for the correlation due to repeated measurements. The model was adjusted for variables used to stratify randomization (age at recruitment, sex, and age at onset). Residuals were examined visually and tested for normality with the Kolmogorov-Smirnov test. To analyze the proportion of days of topical steroid use, we used logistic regression to model the odds per individual with treatment group as the main explanatory variable and adjusted for the variables used for stratified randomization.
Laboratory determinations from blood samples were logtransformed to achieve more normally distributed variables and avoid extreme values. They were then analyzed with linear mixed-effects models (as for the SCORAD although with only 2 time observations, baseline and end of study).
We followed CONSORT recommendations for reporting of randomized clinical trials ( Figure 1 ). All statistical analyses were performed using IBM SPSS statistics, version 22 (SPSS Inc), and R, version 3.2.3.
Results
From March to June 2016, 50 children with a diagnosis of AD were enrolled in the study. All met the criteria for a highquality Mediterranean diet (KIDMED score >7). There were no significant differences in the baseline characteristics between the 2 groups ( Table 1) . Three of the patients in the probiotic group failed to provide data in some of the visits. Two of them declined contact in the second and third visit due to a work-related problem of the parents. Another patient had a concurrent disease unrelated to the treatment and could not provide data on the third visit. All reasons for missing data were unrelated to the treatment or the outcome, so we do not expect effect bias. Because missing data were only 2.5% of follow-up measurements, we decided not to use it and we used only observed data. Patients completed the KIDMED test at inclusion and repeated the test at the end of the intervention. The data show no relevant differences in the KIDMED score between the trial arms at baseline ( 
Effects on Disease Severity
Twenty-two of 23 (96%) patients in the probiotic group and 11 of 24 (46%) in the placebo group improved in the SCORAD index. The mean reduction and 95% confidence interval for the SCORAD index and its components (eczema extension, eczema intensity, and subjective symptoms) for different weeks are shown in Figure 2 , whereas the estimated changes in each trial arm and the differences between the 2 arms (intervention effect) are presented in Table 2 for the total SCORAD index, eTable 4 in Supplement 2 for the subcomponents, and eFigure 1 in Supplement 2 for all. These eTables also give the changes as percentages over baseline values of the variable. At baseline, there were no large differences between arms in any of the variables. As time passed after starting treatment, the differences between arms increased, with better improvements in the probiotic group for total SCORAD, eczema intensity, and eczema spread (with CI excluding the null) but not for subjective symptoms. After 12 weeks of follow-up, the mean change in the SCORAD index (main outcome) was, in relative terms, −83% (95% CI, −95% to −70%) in the probiotic group and −24% (95% CI, −36% to −11%) in the placebo group. This is a difference in effectiveness of −19.2 (95% CI, −23.4 to −15.0) SCORAD points, or −59% (95% CI, −72% to −46%; P < .001), in favor of the probiotic. Patients in both probiotic and placebo groups showed improvement in atopic dermatitis disease activity as measured with Investigator Global Assessment (IGA) over the 12-week study period. Comparison between groups showed significant differences in the number of patients with response to treatment: 21 patients (91%) in the probiotic group achieved IGA scores of 0 or 1 (95% CI, 72%-99%) and 5 patients (21%; 95% CI, 7%-42%) achieved these scores in the placebo group. The percentage of patients with IGA score less than 2, measured at each checkup in weeks 4, 8, and 12, is included in eFigure 2 in Supplement 2.
Effect on Topical Use of Steroids
At the end of follow-up, there were 2032 patient-days of observation in the placebo group and 2084 patient-days in the probiotic group. Steroids were used to treat flares on 220 (10.8%) and 161 (7.7%) patient-days, respectively. The distribution of number of days per individual did not seem to follow a Poisson distribution (eFigure 3 in Supplement 2). Considering that follow-up was approximately 84 days, some individuals used steroids for a large proportion of them. The logistic regression adjusted for baseline stratification variables estimated an odds ratio of 0.63 (95% CI, 0.51-0.78; P < .001) for the effect of the treatment on the reduction of use of corticosteroids. We also did a sensitivity analysis comparing the total number of days of steroid use (including nonflare use). The placebo arm had 336 patient-days of use (16.5%) whereas the probiotic arm had 291 patient-days of use (14.0%). The adjusted logistic regression model produced an odds ratio of 0.77 (95% CI, 0.65-0.91; P < .003), a statistically significant finding of less corticosteroid use in the probiotic group.
Comparison of Blood Marker Levels
Baseline blood marker levels of patients in the probiotic and placebo groups are given in Table 1 . During the 12-week intervention period, no significant differences were observed between the 2 groups in the changes in blood levels of IL-4, IL-5, IL-10, IL-13, eosinophils, IgE, and lactate dehydrogenase (eTable 3 in Supplement 2). 
Adverse Events
No relevant adverse events were associated with drug or placebo intake.
Discussion
Several important studies have explored the efficacy of certain probiotics in the prevention and treatment of AD. Overall, the current evidence suggests that probiotics could be an option to improve moderate and severe AD recovery rates in children and adults; however, to date, there is no strong experimental evidence supporting their effectiveness and safety in clinical practice. 29 Importantly, evidence and clinical trials demonstrating strain-specific effects are lacking.
30-33
The clinical trial reported herein explores the role of a mixture of probiotics administered to patients with moderate AD. Several variables, such as antibiotic use, diet, and other concomitant allergenic diseases were controlled for, and, to avoid bias, all cases included in the study were matched for these variables. Our results suggest that administration of this mixture of probiotics, as adjuvant treatment, may be effective in reducing the SCORAD index and, subsequently, decreasing the use of steroids during AD flares. The response rate was significant when the reduction in baseline SCORAD index was compared between groups ( Table 2 ). The clinical response docu- a Effects are estimated using linear mixed-effects models with a group-by-week interaction, participant-level random intercepts, and adjusted for variables used to stratify randomization.
b These rows are the effects on the rows above divided by baseline SCORAD mean of all participants (32.6) and multiplied by 100. This yields the proportional effect, or percentage effectiveness. The final blend used in the study was selected on the basis of published results and internal unpublished data, as described in the Methods. [24] [25] [26] [27] [28] Two of 3 subcomponents of the SCORAD index (eczema spread and intensity) showed a clear improvement in favor of the probiotic group compared with the placebo group ( Figure 2 , B and C). In contrast, there was no statistically significant difference in subjective symptoms (eTable 4 in Supplement 2 and Figure 2D ). This finding was not due to a lack of effect in the probiotic group, which showed a clinically relevant proportional reduction of 77%, but rather because there was also a reduction in the placebo group of 53%. A possible explanation is that the placebo group was able to reduce symptoms such as pruritus by using more corticosteroids.
After 12 weeks, we saw a slightly greater reduction of IL-4, IL-5, and IL-13 in the probiotic arm compared with placebo (eTable 3 in Supplement 2, last column). This may suggest decreased activity of the T helper 2 cells in the probiotic arm. We did not find statistical significance in any of these differences, but lack of statistical significance does not mean evidence of no difference, especially when the trial was not powered to test differences in cytokines. An investigation of the biological mechanism will require a specifically designed study.
Limitations
The limitations of the study should be considered and clarified through further research. These limitations include the applicability of our results to patients consuming a different diet in different geographic areas, and whether the results can be extended to other population groups such as newborns (<1 year) or adults older than 17 years. In addition, the short follow-up of 12 weeks, the fact that topical corticosteroid dose was not recorded, and the inclusion of patients from a single center should also be considered limitations of this clinical trial. Finally, questions should be answered about adequate dosage, the duration of probiotic administration, and at what age the use of probiotics would be most efficacious. Future trials will be necessary and should consider all these questions to assess the probiotic mixture used in this clinical trial and other specific probiotic strains.
Conclusions
The results of our study indicate a strong positive effect in reducing the SCORAD index and use of topical corticosteroids in the group treated with the probiotic mixture. This evidence supports the efficacy of administering this probiotic mixture to patients with moderate AD and suggests that it could be used more extensively in clinical practice.
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JUSTIFICATION
Atopic dermatitis is a chronic inflammatory skin disease characterized by intense itching, dry skin, and inflammatory exudate, frequently associated with asthma, allergic rhinitis, food allergy and recurrent skin infections secondary (1,2). The first symptoms usually develop during childhood, and about 50% of cases are diagnosed in the first year of life. Atopic dermatitis is a chronic disease, and at least one third of patients continue to suffer from the disease during adulthood (1,2,3) . In developed countries, it affects approximately 10 15% of children under 5 years old at some time. The prevalence in children aged 6 7 years has been estimated at between 1% and 18% in an international trial, and prevalence in childhood is 10% to 20% (2,4). Although the disease, often family related, is not usually serious, and treatment may be simple, atopic dermatitis significantly alters the quality of life of children and adults, having a greater impact on family and economy than psoriasis, and according to some reports, equivalent to other serious diseases such as early onset diabetes mellitus (1,2,4,5).
It has been suggested that atopic dermatitis is a cutaneous manifestation of a systemic disorder, which also leads to other diseases such as asthma, food allergy and allergic rhinitis. The disease has a wide range of clinical symptoms, ranging from minor ones such as pityriasis alba or hand eczema, to more severe forms such as erythrodermic rash (2,7). There are no specific microscopic or laboratory alterations, so the diagnosis of atopic dermatitis is clinical (2, 8 Another aspect besides undertaking diagnosis is the degree of severity of the process in these patients.
To this end, various methods have been developed and criteria used to assess severity and monitor response to treatment, both in clinical trials and observational studies, and even in clinical practice when the patient's progress should be monitored more accurately than that provided by subjective and severe symptoms, respectively (15) . In conducting this clinical trial, internationally accepted criteria will be followed.
There is relative consensus regarding the treatment of atopic dermatitis (1,2,17), and this consensus (8,11) is followed in Spain. Overall, the objectives of treatment are to prevent itching, remove exudate, cure infection, eradicate inflammatory lesions, and prevent relapse. H1
antihistamines are used to eradicate itching and the consequent scratching, which increases infections and inflammatory reaction, although H1 effectiveness is not clearly demonstrated. Traditional H1
antihistamines are used in the acute phase as they seem to produce better results by causing sedation (hydroxyzine, clemastine, dexclorfeniramina), whereas, the latest generation of H1 antihistamines (dexfenfluramine, loratadine, cetirizine and derivatives) can be used after the main outbreak, as they are less sedative; however, their results sometimes have no statistically significant differences compared to a placebo (18) . Nonetheless, in practice, last generation antihistamines are often used since the acute phase, as traditional antihistamines may have adverse effects on the CNS that interfere with daily activities: sedation (ranging from drowsiness to sleep), depression (incoordination, dizziness, lassitude, decreased concentration), and occasionally agitation. Although H1 antihistamines are considered to have a low risk of these adverse effects, the data are extrapolated from their use in patients with allergic pathologies (asthma, allergic rhinitis), and it is unclear that the risks in children with other diseases are similar (34). To prevent recurrence, hygiene and dietary based recommendations are given, to try to avoid contact with triggers and allergens, including food, or skin irritants, as well as heat and excess moisture.
The primary purpose of eczema treatment is to control the inflammatory lesion, which has the secondarily effect of controlling itching. For this, topical corticosteroids (1,2) are used with different strengths depending on the severity of the lesions and the patient's condition. In the initial stage or acute exacerbation of atopic dermatitis, topical corticosteroids are used administered daily, whereas weekly administration can be followed during the remission phase.
Adverse effects of topical corticosteroids pose a limitation or restriction to their use. In these patients, adverse reactions may occur which depend on the power of drug prescribed and the duration of treatment (1,2,8,17,19).
 The most common adverse reactions at the administration site include: skin atrophy, petechiae, atrophic striae, hypertrichosis, depigmentation, telangiectasia, folliculitis, and glaucoma if applied periocularly.
 Also, more serious systemic adverse effects have been described much less frequently:
suppression of the hypothalamic pituitary adrenal axis, growth retardation or cushingoid manifestations.
• Approximately 70 80% of parents and caregivers of children with atopic eczema are concerned about the adverse effects of topical corticosteroids, reducing adherence to treatment (about 25% of them do not apply topical corticosteroids due to anxiety) (17).
The development of new drugs to treat inflammation has been promoted by these adverse effects of corticosteroids, and the lack of response to them in some patients. Among the best studied are calcineurin inhibitors (tacrolimus and pimecrolimus) for topical administration (2, 11) . These drugs inhibit the activity of cells involved in the immune response, including T cells, and reduce the production of cytokines and inflammatory response, and importantly they do not appear to increase the risk of infection or produce skin atrophy. The potential risk of the absorption of these drugs, and their reaching systemically active concentrations has only been detected with tacrolimus. However, there are still doubts about the safety of these drugs in long term treatments, such as increased risk of cancer, which have been raised but not confirmed. Consequently, the prospectus of products containing tacrolimus or pimecrolimus for topical treatment of atopic dermatitis state that they should only be used in children over 2 years old, for whom the use of topical corticosteroids is not recommended, or in patients for whom they have previously failed ( 20,21). Furthermore: 
OBJECTIVES
The purpose of this trial is to evaluate the efficacy of the Probiotic CBP 004024 in reducing, on the one hand, the symptoms of moderate atopic dermatitis (SCORAD index) and, on the other hand, the use of topical corticosteroids, antihistamines and systemic corticosteroids (according to the criteria of Hanifin and Rajka, with index SCORAD 20 to 40, inclusive), in patients aged 4 17 years who require these drugs due to disease outbreaks and who use or are prescribed topical corticosteroids to treat outbreaks of atopic dermatitis.
Trial variables:
Primary variable:
SCORAD index score: baseline and monthly at medical check ups until the end of the study period (12 weeks).
Evaluate the number of days that each patient requires administration of topical corticosteroids during oubreaks, based on the patient's logbook. Disease outbreak is understood to mean that due to the disease the patient requires the use of topical corticosteroids for at least three consecutive days.
Other variables:
• The number of outbreaks quantified at each check up, based on logbook data and clinical examination.
• The use of antihistamines and the need for new treatments based on the logbook.
• The Investigators' Global Assessment (IGA) score is measured at each check up. IGA <2 is considered a therapeutic success.
• Adverse events are recorded at each check up, based on the patient's logbook and clinical examination Primary Objective:
The main objective of the trial is dual. On the one hand to assess the percentage of days when topical corticosteroids are used during disease outbreaks during the 12 week treatment period with the probiotic or a placebo, and on the other, to evaluate the variation and differences in the SCORAD index (Annex III) between groups (probiotic versus placebo) at 4, 8 and 12 weeks of the trial period. • Patients with KIDMED score for Mediterranean Diet under 8 points.
• Patients with intolerance to gluten and / or lactose.
• Patients who have participated in research studies with drugs in the 3 months prior to the trial.
 Criteria for patient withdrawal from therapy or assessment:
If during the course of the trial a patient needs to take any kind of concurrent treatment they must notify the trial investigator, who should take note of the dose, reason, route of administration, etc. on an individual monitoring sheet.
Those patients requiring systemic corticosteroid therapy during the trial for over five days if under 10 years of age, or more than 7 days if over 10 years of age, will be removed from the trial.
Patients not taking the probiotic for more than 8 consecutive days (10% of treatment time)
will also be removed.
Protocol and statistical analysis
Trial framework N= Delivery of probiotic / placebo
Return and tally of capsules Usual treatment: emollients, antihistamines and topical corticosteroids
Sample size estimation
Previous data from studies in adults and children, with similar diagnosis and moderate severity of atopic dermatitis, show that in patients and conditions similar to those in this trial, the placebo group used topical corticosteroids on 50% of the days during the trial period. In these trials, there are no data on the use of topical corticosteroids exclusively in disease outbreaks and therefore this value can not be estimated. Furthermore, in clinical trials in the same conditions described and reproduced in our study, comparing the placebo group with the probiotic group, there was a 30% difference in clinical improvement as evaluated by the SCORAD index (15% vs 45%).
Assuming a similar effect in response to the oral placebo in this clinical trial and a reduction equal to or greater than 33% compared to that observed in the placebo group, together with an estimated 5% loss in trial subjects, the sample size required for alpha 0.05 and a statistical power of 80% was 25 patients per group of intervention. For safety and tolerability assessment, the appropriate specifications will be made for each and every variable that appears (according to adverse events). These will be tabulated by treatment group, age, sex, and issues that may influence the occurrence and / or severity of adverse events. Also a descriptive analysis will be made of the changes in health indicator variables (obtained from tests performed in the clinical check up). The safety parameters will be expressed individually and as means ± standard deviation values
Planned
Exposure to treatment and therapeutic compliance
The consumption antihistamines and antibiotics will be evaluated in the same way as described for the analysis of topical corticosteroids consumption.
A descriptive analysis will be conducted per group for the atopic dermatitis treatments administered during the trial.
A descriptive analysis will be conducted of therapeutic compliance to the masked product used in the trial. Data will be tabulated by treatment group, age, sex, and aspects considered of interest.
11.5
Trial population and homogeneity analysis: 
Other efficacy analysis
a. Exposure to other treatment: Antihistamine and systemic corticosteroids consumption will be evaluated in the same way as described for the analysis topical corticosteroids, as pre specified secondary variable.
b. The trends and values of Investigator Global Assesment (IGA) scale will be analyzed at each check up during the trial.
c. Patients will belong to one of two groups depending on whether their IgE values in blood are higher or lower than 100 IU / ml, and the development of each group will be analyzed separately.
ETHICS AND LEGISLATION IN RESEARCH STUDIES
The Informed consent will be provided in a standard written document, in language easily understood by the participant. The subject/participant shall be given ample time to read and understand explanations before dating and signing the informed consent, and shall receive a copy of the signed document. No subject will be included in the trial without having given written informed consent.
Prior informed consent shall be obtained from a parent or legal representative; the agreement will reflect the presumed willingness of the child. When the child is 12 or older, he/she will also provide his/her consent to participate in the trial. The minor will receive information about the trial, the risks and benefits appropriate to his/her capacity for understanding. In compliance with the provisions of Treatment will be assigned by 1:1 randomization blocks, stratified taking into account the following three variables: sex and age of the patient (under 12 years of age or over) and age at disease onset (before or after 4 years of age).
14. Treatment
Treatment period
The treatment period will be 12 weeks. After the trial inclusion consultation (baseline) and assigned treatment, seven check ups will be programmed, which will take place at 4, 8 and 12 weeks from the start of treatment with the probiotic or placebo, and SCORAD will be performed, and each patient's Data Collection Logbook (DCL) will be reviewed at weeks 2, 6 and 10.
Treatment description and definition of exposure
Patients will receive Probiotic or an identical looking masked placebo (double blind). 
Topical corticosteroids:
To treat outbreaks of Methylprednisolone aceponate, a thin layer is applied once a day to the affected area and rubbed lightly.
In general, treatment duration should not exceed two weeks. As a general rule, the duration of treatment in children should be limited to a minimum. If excessive dryness of the skin occurs during treatment with topical steroid, the use of an emollient adjunctive therapy is recommended.
Systemic corticosteroids:
Should systemic corticosteroids be required, Deflazacort will be prescribed.
Antihistamine medication
Desloratadine will be used to treat itching, in either syrup or tablets. Children 7 to 11 years: 5 ml of syrup once a day (2.5 mg desloratadine). Children over 12 and adults: one tablet (5 mg of desloratadine) once a day.
Topical antibiotics
Ac Fusidic antibiotic will be used, an antibiotic commonly prescribed for infected atopic dermatitis.
Delivery of medication
The study drugs will be delivered under the conditions established by the regulations in force in the pharmacy of the center involved. All these medicines shall be used in accordance with the specifications given in the technical specifications of the products. The sponsor/promoter shall provide:
 Probiotic CBP 004024 vs placebo 14.2.2 Data collection.
All medications taken by the patient during the study will be recorded in Data Collection Logbook (DCL) specifying the doses, route of administration and duration of treatment (start end date).
Information on study medication will be recorded in the corresponding DCL. The investigator and / or trial collaborators will assess fulfillment/adherence at each check up by counting the returned capsules and the information provided by the patient. All medication dispensed and returned during the trial will be recorded in the DCL.
RESEARCH PROCEDURE
Determination of sample size
Previous data from studies in adults and children with similar diagnosis and moderate severity, showed that in the placebo group, topical corticosteroids were used 52 ± 24.6% of the days during the trial, in patients and conditions similar to those in this study. Assuming a similar effect in response to oral placebo, and a 60% reduction in the number of days of treatment with topical corticosteroids in the group treated with Probiotic, with an estimated 5% of study subjects losses, group of 25 patients per group would be required to detect such differences as statistically significant with a power of 80%. To carry out the trial 25 patients are randomized to each of the two groups.
Trial framework
The trial will last a total of 12 WEEKS from the recruitment of patients to the last check up, and will be The following clinical tests will be performed for each subject:
 Medical record that includes personal and family history and anamnesis for appliances.
 Complete physical examination including height, temperature and body weight.  Routine tests of hematology, biochemistry, IgE and urinalysis. These laboratory tests are considered routine in the diagnosis and monitoring of these patients, and will only be performed at check ups 1 and 7.
 Determination of bacterial DNA in blood. Interleukins IL 5, IL 10, IL 13, IL 31  Determination of the microbiota from feces sample.
 Urine based pregnancy test (women of childbearing age).
 Once included in the study, each subject will receive a numbered box, coded and labeled in accordance with current regulations, with capsules for the first month of treatment. All subjects will receive a greater number of capsules than that required by treatment regimen assigned, in order to enable accurate tally of the consumed units and evaluate patient compliance. The subject and his/her guardian will be clearly informed how to take the capsule every day, ingesting it before meals.
Check ups 3, 5 and 7:
Assessment will be made of disease outbreaks, treatments and problems Evaluation of atopic dermatitis
Adverse events will be assessed following the procedures established in the protocol. All adverse events reported by the patient will be recorded, specifying date of commencement and termination, and treatment received, if applicable.
At check ups 3, 5 and 7 the subject shall return the box with the leftover medication, and be given a new box with treatment corresponding to the following month, with leftover capsules included. The last box will be returned by the subject at check up No. 7.
Check ups 2, 4 and 6:
Check ups will be held within 15 days of each main consultancy to review the patient's DCL and review the patient's progress. SCORAD will not be performed.
Check up 7: End of trial check up
Evaluation of atopic dermatitis
The assessment of adverse events will be performed following the procedures established in the protocol. All adverse events reported by the patient will be recorded, specifying date of commencement and termination, and treatment received if applicable.
A complete check up of the patient will be performed, including analytical and other diagnostic examinations, evaluation of adverse events and evolution of atopic dermatitis, information about medications used and number of outbreaks.
Analytical assessment
Laboratory tests 15 Variables and measuring instruments. Definition and description of measurements iii. The IGA is measured at each check up as established in Annex IV.
iv. Adverse events are recorded at each check up, based on information from the patient's logbook and the clinical examination.
STATISTICAL ANALYSIS
Quality control of the data submitted for analysis:
All the analyzed data will be entered into a database built in ACCESS version 2007 platform using a double data entry procedure. Any doubts about the information provided in the Data Collection Logbooks will be clarified by sending appropriate consultations to the trial supervisor. The data analyzed will correspond to those resulting after settling disagreements in the double entry and consultations on anomalous data in the logbooks.
A randomization table is included as an additional table in the database.
16.2 Transfer of data from the database to the statistical analysis software SPSS (SPSS20.0 for Windows):
In each of the statistical analyzes carried out, a specific query is performed across data from each check up required for analysis with the treatment assigned in the randomization table. The resulting query is imported directly from Microsoft Access to SPSS using the specific function available for this in SPSS 20.0. Once the data from a query have been uploaded in an SPSS file, parity is found in the data between the two files (1 record in 5 is checked for the parity of each and every one of the variables in the file).
SPSS files in YES / NO variables have been coded as 1/0.
Primary efficacy analysis
Analysis will be made of the percentage of days when topical corticosteroids are used, calculated as the number of days in treatment with topical corticosteroids divided by the number of days in the study, and global data will be compared at 4, 8 and 12 weeks of treatment using the Wilcoxon test with a level of statistical significance of 5%. An analysis by intention to treat and per protocol will be performed in accordance with the provisions of the protocol.
Primary endpoint: the primary objective of the study is to compare the percentage of days when topical corticosteroids are used during 12 weeks of treatment with Probiotic or placebo:
Intention-to-treat analysis:
Percentage of days when topical corticosteroids are used during 12 weeks of treatment: this is analyzed by counting the number of days the patient has taken topical corticosteroids (Metilprednisolona Aceponato) throughout the trial, divided by the number of days of participation in the trial. In those patients whose participation in the trial ends before 12 weeks, the percentage of days that topical corticosteroids are used is calculated for the interval between the penultimate and the last check ups attended by the patient. This percentage is applied to the unattended check ups up until the end of time foreseen for participation in the study (3 months = 90 days).
MODIFICATIONS TO THE PROTOCOL:
No modifications will be made to the protocol approved by the CEIC and the Spanish Medicines Agency. 
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS
eTable 3. Estimation of the effect of intervention in laboratory parameters
Parameters in the log scale Baseline (1) Follow up (2) Log ( 
